Horizon Scanning

It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.

The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:

  • Is this emerging technology new or replacing an existing technology?
  • Where is this technology in the FDA regulatory process?
  • When will this technology be commercially available in the market?
  • What is the projected use, cost, and financial impact of this technology?

Rituxan® (Rituximab)

An intravenous anti-CD20 monoclonal antibody for the treatment of multiple sclerosis.  

Arzerra™ (Ofatumumab)

An intravenously administered biologic for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.

DuraSeal Xact™ Sealant System

A bioresorbable polyethylene glycol hydrogel for sealing dural incisions during lumbar spinal surgery to prevent cerebrospinal fluid leakage.